In Brief: Dapagliflozin (Farxiga) for Chronic Kidney Disease

Date: July 26, 2021
Issue #: 
1629Summary: 
The sodium-glucose cotransporter 2 (SGLT2) inhibitor
dapagliflozin (Farxiga– AstraZeneca) has been
approved by the FDA for treatment of adults with
chronic kidney disease (CKD) at risk of progression
(not defined in the label). Dapagliflozin is the first
SGLT2 inhibitor to be approved in the US for treatment
of CKD.

Source: The Medical Letter - July 9, 2021 Category: Drugs & Pharmacology Authors: admin Tags: chronic kidney disease dapagliflozin Farxiga Forxiga Source Type: research